By Chisom Juanita Mefor
Cancer is increasingly visible in Nigeria’s health landscape. What was once perceived as a relatively uncommon disease is now present in hospitals across the country and in the daily realities of many families. The 2026–2030 National Cancer Control Plan (NCCP) provides one of the most comprehensive assessments to date of this growing challenge.
Beyond statistics, the plan reveals a deeper truth: cancer in Nigeria is not only a clinical problem. It is a systemic issue shaped by health infrastructure, diagnostic capacity, financing mechanisms, and the availability of reliable clinical data. Understanding the country’s cancer burden therefore requires looking not only at incidence and mortality rates, but also at how patients navigate the healthcare system and where that system succeeds—or fails—in delivering timely care.
The Growing Burden of Cancer
Nigeria records thousands of new cancer diagnoses each year, although the true number is likely higher due to gaps in surveillance and reporting. Breast, cervical, and prostate cancers account for a large proportion of cases nationally, while head and neck cancers and childhood cancers also contribute significantly to the disease burden.
These patterns reflect a combination of biological risk factors and broader structural realities. Limited screening programs, uneven diagnostic capacity, and delayed health-seeking behavior all influence how and when cancer is detected.
One of the clearest themes emerging from the National Cancer Control Plan is late presentation. Many patients arrive at tertiary hospitals only after symptoms have progressed to advanced stages of disease. By that point, treatment options are more complex, survival rates are lower, and the financial and emotional burden on families increases dramatically.
Cancer statistics often appear abstract on paper. In reality, each number represents a patient navigating a complex health system while searching for diagnosis, treatment, and hope.
Late Diagnosis and the Patient Journey
Childhood cancers illustrate these challenges particularly clearly. According to GLOBOCAN estimates, nearly 6,000 new childhood cancer cases were diagnosed in Nigeria in 2022. Many of these cases are detected at advanced stages.
Consider the experience of Aisha, a twelve-year-old from Kano who developed swelling in her jaw. What initially appeared to be a minor infection persisted for weeks before her family sought additional medical attention. After traveling more than 300 kilometers to reach a tertiary hospital in Kaduna, she was diagnosed with Burkitt lymphoma, a fast-growing but often treatable cancer when detected early.
Her experience is not unusual. Delayed diagnosis, referral barriers, and geographic disparities frequently mean that patients reach specialized cancer care only after the disease has progressed.
These stories highlight a critical reality: the patient journey through the health system often determines outcomes as much as the disease itself.
Gender and Demographic Patterns
The cancer landscape in Nigeria also reflects clear demographic patterns.
Women bear a particularly heavy burden through breast and cervical cancers, both of which remain leading causes of cancer-related illness and death. Cervical cancer is especially striking because it is largely preventable through vaccination and early screening, yet continues to affect thousands of women each year.
Among men, prostate cancer remains one of the most commonly diagnosed cancers. Many cases are identified only when symptoms become severe, reflecting limited routine screening and delayed health-seeking behavior.
Children represent another vulnerable population. Although childhood cancers are less common than adult cancers, survival rates in many African settings remain significantly lower than in high-income countries. Nigeria has only a small number of trained pediatric oncologists relative to its population, and specialized treatment facilities are concentrated in a handful of major cities.
As a result, families frequently travel long distances to access care, adding financial and emotional strain to an already difficult diagnosis.
Health System Capacity and Access
Nigeria’s healthcare system operates across federal, state, and local levels. In theory, this structure allows patients to move through a referral pathway from primary health centers to specialized hospitals.
In practice, however, cancer care remains heavily concentrated at tertiary institutions.
Although the country has more than 80 federal tertiary health facilities, only a limited number provide comprehensive oncology services that include surgery, chemotherapy, and radiotherapy.
For many patients, accessing treatment means traveling across state lines.
A prostate cancer patient from Anambra State may travel several hours to reach a teaching hospital in Lagos for radiotherapy. Even where facilities exist, travel distance alone can create barriers to consistent treatment. Long journeys often lead to missed appointments, delayed therapy, and additional costs for patients and families.
Diagnostic capacity also remains uneven. Pathology services, molecular testing, and advanced imaging are concentrated in a small number of facilities. Workforce shortages and equipment downtime further complicate the diagnostic process.
Because cancer outcomes depend heavily on early detection and timely treatment, these delays can have serious consequences.
The Financial Burden of Treatment
For many Nigerian families, the greatest barrier to cancer care is cost.
A full course of chemotherapy may range from ₦1.3 million to ₦28 million, depending on the type of cancer and treatment protocol. Radiation therapy can cost between ₦800,000 and ₦3 million.
These costs far exceed the financial capacity of most households.
Health insurance coverage remains limited, and out-of-pocket payments account for the majority of healthcare expenditures in Nigeria. As a result, many patients delay treatment, discontinue therapy midway, or abandon care entirely.
Programs such as the Cancer Access Partnership (CAP) have helped improve access to certain medications, but affordability remains a defining challenge within Nigeria’s cancer landscape.
Data, Research, and the Infrastructure Gap
Beyond workforce, facilities, and financing, another factor quietly shapes cancer outcomes: the availability of reliable clinical data.
Across many hospitals, patient records are captured through fragmented systems that make it difficult to combine and analyze information at scale. Without standardized datasets, researchers and policymakers struggle to identify patterns in disease progression, treatment response, or regional disparities.
High-quality clinical data is essential for improving cancer care. It allows researchers to evaluate outcomes, clinicians to refine treatment strategies, and policymakers to design interventions grounded in evidence.
Without structured and interoperable datasets, the health system operates with limited visibility into what is working—and what is not.
Building the Research Infrastructure for the Future
Addressing these challenges requires more than expanding hospitals or purchasing new equipment. It also requires strengthening the research infrastructure that supports evidence-based cancer care.
Institutions such as the Claremont Amany Institute (CAI) are working to address this gap by supporting cancer research infrastructure across Africa. Through initiatives such as the African Hematologic Cancer Biobank, the institute is helping build high-quality repositories of biospecimens linked to structured clinical and genomic data.
When biospecimens are paired with standardized clinical datasets, researchers can study disease patterns across populations, evaluate treatment outcomes, and investigate genetic drivers of cancer with greater precision.
In this way, everyday patient care becomes a foundation for scientific discovery.
Looking Ahead
The National Cancer Control Plan provides an important snapshot of Nigeria’s current cancer landscape. It highlights persistent challenges, including late diagnosis, limited specialist workforce, uneven access to care, and high treatment costs.
At the same time, it points toward areas of progress. Expanded treatment facilities, pediatric oncology collaborations, improved health data systems, and stronger national coordination all suggest that a more structured response is beginning to take shape.
Improving cancer outcomes in Nigeria will require sustained investment, thoughtful policy, and collaboration across healthcare institutions, research organizations, and government agencies.
Above all, it will require keeping patients and families at the center of the system.
A national cancer control plan is ultimately more than a policy document. It represents a commitment: that fewer Nigerians will face cancer without timely diagnosis, effective treatment, and compassionate care.